Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392678 · ClinicalTrials.gov registry record · Phase 2
Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)
A Phase 2 study of Type 2 Diabetes, sponsored by Joslin Diabetes Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 277
- Enrollment target
- 16
- Study locations
NCT00392678: Completed Phase 2 study of Type 2 Diabetes, sponsored by Joslin Diabetes Center.
NCT00392678 is a Phase 2 study of Type 2 Diabetes that has completed, run by Joslin Diabetes Center. The registered enrollment target is 277 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (93% lower). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00392678, a Phase 2 study of Type 2 Diabetes, has completed, sponsored by Joslin Diabetes Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 277 participants
- Enrollment target
- 16
- Study locations
Study Summary
Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we will determine whether salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2 diabetes. The study will determine whether salicylates represent a new pharmacological option for diabetes management. The study is conducted in two stages. The first stage is a dose ranging study, administering salsalate compared to placebo over three months. The primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and cardiac risk. The second stage is a second trial and posted under alternate registration.
Primary Outcome
The primary outcome for the TINSAL-T2D study is change in HbA1c level from baseline to week 14 (stage 1) in the intent-to-treat (ITT) population with last observation carried forward.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Salsalate
Study Locations (16)
New York
- Kaleida Health Center - Buffalo
- North Shore Diabetes and Endocrine Associates - New Hyde Park
- Columbia University - New York
- University of Rochester Medical Center - Rochester
Georgia
- Kaiser Permanente - Atlanta
- Emory School of Medicine - Atlanta
Connecticut
- Chapel Medical Group - New Haven
District of Columbia
- MedStar Research Institute - Washington D.C.
Florida
- Endocrine Clinical Research - Winter Park
Illinois
- University of Illinois at Chicago - Chicago
Louisiana
- Tulane University - New Orleans
Massachusetts
- Joslin Diabetes Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT00392678 record still lists
NCT00392678 is an interventional study that assigns participants to a tested intervention. The registered 277 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00392678 lists 16 locations in 12 states (New York, Georgia, Connecticut).
Frequently Asked Questions
What is clinical trial NCT00392678 about?
NCT00392678 is a clinical study titled "Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)". Growing evidence over recent years supports a potential role for low grade chronic inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we will determine whether salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effec...
What is the current status of trial NCT00392678?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 277 participants. The study started on 2006-10. Estimated completion is 2010-12.
What conditions does trial NCT00392678 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT00392678?
The interventions under investigation include: Placebo (DRUG), Salsalate (DRUG).
Who is sponsoring clinical trial NCT00392678?
This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00392678 being conducted?
This trial has 16 study locations across Connecticut, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00392678's enrollment target sits among peer trials
277 76th of 327 higher than 252 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Renal Mechanism of SGLT2 Inhibition
RECRUITING · Phase 2
-
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
RECRUITING · Phase 2
-
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
RECRUITING · Phase 2
-
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
RECRUITING · Phase 2
-
NAD Augmentation in Diabetes Kidney Disease
RECRUITING · Phase 2
-
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05818683 · 277 participants · Phase 1
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
- NCT06789913 · 277 participants · Phase 2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
- NCT04586959 · 278 participants · NA
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- NCT05010148 · 278 participants · Phase 3
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia